BCBS Arizona

Does BCBS Arizona cover Ozempic?

Quick answer · Type 2 Diabetes

BCBS Arizona covers Ozempic for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered with requirements. A1C of 6.5% or higher
  • ACA Marketplace: Covered with requirements. A1C of 6.5% or higher

Last verified June 2, 2026. Policy effective April 1, 2026. Source: Download. How we verify this data →

Check your card for your exact plan →

Ozempic for Type 2 Diabetes

What BCBS Arizona requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Type 2 Diabetes - Initial Approval

All of:

  • Diagnosis of Type 2 diabetes as adjunct to diet and exercise to improve glycemic control
  • Medication is NOT solely being used for weight loss
  • Age consistent with FDA labeling
  • Medical regimen includes standard of care for type 2 diabetes
  • Does not have type 1 diabetes
  • No severe gastrointestinal disease (gastroparesis)
  • No personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • No concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
  • Failure, contraindication, or intolerance with THREE generic equivalents (if available) for at least three months each

Plus any one of:

  • A1C >= 6.5%
  • Fasting plasma glucose >= 126 mg/dL
  • 2-hour plasma glucose >= 200 mg/dL during oral glucose tolerance test
  • Random plasma glucose >= 200 mg/dL

Documentation to bring

  • Completed prior authorization request form signed by prescribing provider
  • Chart notes
  • Lab results confirming T2DM diagnosis (A1C >= 6.5%, fasting plasma glucose >= 126 mg/dL, 2-hour PG >= 200 mg/dL during OGTT, or random plasma glucose >= 200 mg/dL)
  • Documentation of failure, contraindication, or intolerance to three generic equivalent medications for at least three months each
  • Supporting clinical documentation confirming standard of care for type 2 diabetes is in place

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for improvement in A1C and Decrease in A1C from baseline; adherence to prescribed therapy regimen for diabetes including diet and exercise.

Not covered when

  • Severe gastrointestinal disease (gastroparesis)
  • Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • Concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
  • Medication used solely for weight loss (not covered under this indication)
  • Type 1 diabetes

Policy note: Policy applies to Commercial and/or Marketplace plans only. At continuation, pancreatitis, severe hypersensitivity reaction, acute kidney injury, drug-induced immune mediated thrombocytopenia, and acute gallbladder disease are additional safety exclusions. Manufacturer samples and coupons not counted toward continuation eligibility.

Policy effective April 1, 2026 · verified June 2, 2026 · source: Download

ACA Marketplace

Covered with requirements

What you need to qualify

  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Type 2 Diabetes - Initial Approval

All of:

  • Diagnosis of Type 2 diabetes as adjunct to diet and exercise to improve glycemic control
  • Medication is NOT solely being used for weight loss
  • Age consistent with FDA labeling
  • Medical regimen includes standard of care for type 2 diabetes
  • Does not have type 1 diabetes
  • No severe gastrointestinal disease (gastroparesis)
  • No personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • No concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
  • Failure, contraindication, or intolerance with THREE generic equivalents (if available) for at least three months each

Plus any one of:

  • A1C >= 6.5%
  • Fasting plasma glucose >= 126 mg/dL
  • 2-hour plasma glucose >= 200 mg/dL during oral glucose tolerance test
  • Random plasma glucose >= 200 mg/dL

Documentation to bring

  • Completed prior authorization request form signed by prescribing provider
  • Chart notes
  • Lab results confirming T2DM diagnosis (A1C >= 6.5%, fasting plasma glucose >= 126 mg/dL, 2-hour PG >= 200 mg/dL during OGTT, or random plasma glucose >= 200 mg/dL)
  • Documentation of failure, contraindication, or intolerance to three generic equivalent medications for at least three months each
  • Supporting clinical documentation confirming standard of care for type 2 diabetes is in place

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for improvement in A1C and Decrease in A1C from baseline; adherence to prescribed therapy regimen for diabetes including diet and exercise.

Not covered when

  • Severe gastrointestinal disease (gastroparesis)
  • Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • Concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
  • Medication used solely for weight loss (not covered under this indication)
  • Type 1 diabetes

Policy note: Policy applies to Commercial and/or Marketplace plans only. At continuation, pancreatitis, severe hypersensitivity reaction, acute kidney injury, drug-induced immune mediated thrombocytopenia, and acute gallbladder disease are additional safety exclusions. Manufacturer samples and coupons not counted toward continuation eligibility.

Policy effective April 1, 2026 · verified June 2, 2026 · source: Download

Ozempic for Heart Disease Risk Reduction

What BCBS Arizona requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • A1C of 6.5% or higher
  • Established cardiovascular disease (ASCVD)
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction in T2DM with Established ASCVD or High ASCVD Risk

All of:

  • Diagnosis of Type 2 diabetes
  • Established clinical atherosclerotic cardiovascular disease (ASCVD) or high ASCVD risk
  • Goal is to reduce major adverse cardiovascular events
  • Age consistent with FDA labeling
  • Medical regimen includes standard of care for type 2 diabetes and cardiovascular disease
  • Does not have type 1 diabetes
  • No severe gastrointestinal disease (gastroparesis)
  • No personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • No concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
  • Failure, contraindication, or intolerance with THREE generic equivalents (if available) for at least three months each

Plus any one of:

  • A1C >= 6.5%
  • Fasting plasma glucose >= 126 mg/dL
  • 2-hour plasma glucose >= 200 mg/dL during oral glucose tolerance test
  • Random plasma glucose >= 200 mg/dL

Documentation to bring

  • Completed prior authorization request form signed by prescribing provider
  • Chart notes documenting established ASCVD or high ASCVD risk
  • Lab results confirming T2DM diagnosis (A1C, fasting plasma glucose, or OGTT values)
  • Documentation of failure, contraindication, or intolerance to three generic equivalent medications for at least three months each
  • Supporting clinical documentation confirming standard of care for type 2 diabetes and cardiovascular disease is in place

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for improvement in A1C and Decrease in A1C from baseline; adherence to prescribed therapy regimen for diabetes including diet and exercise.

Not covered when

  • Severe gastrointestinal disease (gastroparesis)
  • Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • Concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
  • Type 1 diabetes

Policy note: This indication requires T2DM as an underlying condition — it is NOT a diabetes-free CV risk reduction pathway. The policy covers this indication for Ozempic specifically for reducing major adverse cardiovascular events (CV death, non-fatal MI, non-fatal stroke) in adults with T2DM and established CV disease or high ASCVD risk. Standard of care for 'other disease of concern' (CV disease) must also be included in medical regimen.

Policy effective April 1, 2026 · verified June 2, 2026 · source: Download

ACA Marketplace

Covered with requirements

What you need to qualify

  • A1C of 6.5% or higher
  • Established cardiovascular disease (ASCVD)
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction in T2DM with Established ASCVD or High ASCVD Risk

All of:

  • Diagnosis of Type 2 diabetes
  • Established clinical atherosclerotic cardiovascular disease (ASCVD) or high ASCVD risk
  • Goal is to reduce major adverse cardiovascular events
  • Age consistent with FDA labeling
  • Medical regimen includes standard of care for type 2 diabetes and cardiovascular disease
  • Does not have type 1 diabetes
  • No severe gastrointestinal disease (gastroparesis)
  • No personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • No concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
  • Failure, contraindication, or intolerance with THREE generic equivalents (if available) for at least three months each

Plus any one of:

  • A1C >= 6.5%
  • Fasting plasma glucose >= 126 mg/dL
  • 2-hour plasma glucose >= 200 mg/dL during oral glucose tolerance test
  • Random plasma glucose >= 200 mg/dL

Documentation to bring

  • Completed prior authorization request form signed by prescribing provider
  • Chart notes documenting established ASCVD or high ASCVD risk
  • Lab results confirming T2DM diagnosis (A1C, fasting plasma glucose, or OGTT values)
  • Documentation of failure, contraindication, or intolerance to three generic equivalent medications for at least three months each
  • Supporting clinical documentation confirming standard of care for type 2 diabetes and cardiovascular disease is in place

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for improvement in A1C and Decrease in A1C from baseline; adherence to prescribed therapy regimen for diabetes including diet and exercise.

Not covered when

  • Severe gastrointestinal disease (gastroparesis)
  • Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • Concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
  • Type 1 diabetes

Policy note: This indication requires T2DM as an underlying condition — it is NOT a diabetes-free CV risk reduction pathway. The policy covers this indication for Ozempic specifically for reducing major adverse cardiovascular events (CV death, non-fatal MI, non-fatal stroke) in adults with T2DM and established CV disease or high ASCVD risk. Standard of care for 'other disease of concern' (CV disease) must also be included in medical regimen.

Policy effective April 1, 2026 · verified June 2, 2026 · source: Download

Ozempic for Kidney Disease (CKD)

What BCBS Arizona requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

CKD with T2DM - Initial Approval

All of:

  • Diagnosis of Type 2 diabetes
  • Chronic kidney disease (CKD) diagnosis
  • Goal is to reduce risk of sustained eGFR decline, end-stage kidney disease, or cardiovascular death
  • Age consistent with FDA labeling
  • Medical regimen includes standard of care for both type 2 diabetes and CKD
  • Does not have type 1 diabetes
  • No severe gastrointestinal disease (gastroparesis)
  • No personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • No concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
  • Failure, contraindication, or intolerance with THREE generic equivalents (if available) for at least three months each

Plus any one of:

  • A1C >= 6.5%
  • Fasting plasma glucose >= 126 mg/dL
  • 2-hour plasma glucose >= 200 mg/dL during oral glucose tolerance test
  • Random plasma glucose >= 200 mg/dL

Documentation to bring

  • Completed prior authorization request form signed by prescribing provider
  • Chart notes documenting CKD diagnosis
  • Lab results confirming T2DM diagnosis (A1C, fasting plasma glucose, or OGTT values)
  • Documentation of failure, contraindication, or intolerance to three generic equivalent medications for at least three months each
  • Supporting clinical documentation confirming standard of care for type 2 diabetes and CKD is in place

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for improvement in A1C and Decrease in A1C from baseline; adherence to prescribed therapy regimen for diabetes including diet and exercise.

Not covered when

  • Severe gastrointestinal disease (gastroparesis)
  • Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • Concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
  • Type 1 diabetes

Policy note: Ozempic is specifically listed as the only agent covered for the CKD indication in this policy. This indication requires T2DM as an underlying condition. The policy states coverage is to reduce risk of sustained decline in eGFR, end-stage kidney disease, and cardiovascular death. No specific eGFR or UACR thresholds are defined in the policy; standard of care for the CKD 'other disease of concern' must be in place.

Policy effective April 1, 2026 · verified June 2, 2026 · source: Download

ACA Marketplace

Covered with requirements

What you need to qualify

  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

CKD with T2DM - Initial Approval

All of:

  • Diagnosis of Type 2 diabetes
  • Chronic kidney disease (CKD) diagnosis
  • Goal is to reduce risk of sustained eGFR decline, end-stage kidney disease, or cardiovascular death
  • Age consistent with FDA labeling
  • Medical regimen includes standard of care for both type 2 diabetes and CKD
  • Does not have type 1 diabetes
  • No severe gastrointestinal disease (gastroparesis)
  • No personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • No concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
  • Failure, contraindication, or intolerance with THREE generic equivalents (if available) for at least three months each

Plus any one of:

  • A1C >= 6.5%
  • Fasting plasma glucose >= 126 mg/dL
  • 2-hour plasma glucose >= 200 mg/dL during oral glucose tolerance test
  • Random plasma glucose >= 200 mg/dL

Documentation to bring

  • Completed prior authorization request form signed by prescribing provider
  • Chart notes documenting CKD diagnosis
  • Lab results confirming T2DM diagnosis (A1C, fasting plasma glucose, or OGTT values)
  • Documentation of failure, contraindication, or intolerance to three generic equivalent medications for at least three months each
  • Supporting clinical documentation confirming standard of care for type 2 diabetes and CKD is in place

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for improvement in A1C and Decrease in A1C from baseline; adherence to prescribed therapy regimen for diabetes including diet and exercise.

Not covered when

  • Severe gastrointestinal disease (gastroparesis)
  • Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
  • Concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
  • Type 1 diabetes

Policy note: Ozempic is specifically listed as the only agent covered for the CKD indication in this policy. This indication requires T2DM as an underlying condition. The policy states coverage is to reduce risk of sustained decline in eGFR, end-stage kidney disease, and cardiovascular death. No specific eGFR or UACR thresholds are defined in the policy; standard of care for the CKD 'other disease of concern' must be in place.

Policy effective April 1, 2026 · verified June 2, 2026 · source: Download

Why Ozempic requests get denied by BCBS Arizona

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Ozempic and Wegovy are the same molecule with different approved uses; a request for Ozempic under a diagnosis that matches Wegovy is routinely denied.
  2. No recent A1C result on file.

Frequently asked questions

Does BCBS Arizona cover Ozempic?
BCBS Arizona covers Ozempic for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
How long does a Ozempic approval last with BCBS Arizona?
Initial approvals last 12 months, and renewals are granted in 12-month periods.
What does BCBS Arizona require to renew Ozempic?
Improvement in A1C and Decrease in A1C from baseline; adherence to prescribed therapy regimen for diabetes including diet and exercise.
How current is this information?
This page reflects BCBS Arizona's written policy as of April 1, 2026, last verified against the source document on June 2, 2026.

Other medications under BCBS Arizona

Ozempic coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Arizona's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.